| CAS NO: | 939228-52-1 |
| 包装 | 价格(元) |
| 5mg | 询价 |
| 10mg | 询价 |
| 25mg | 询价 |
| 50mg | 询价 |
| 100mg | 询价 |
| Cas No. | 939228-52-1 |
| 别名 | 2-(4-((2-氨基-4-氧代噻唑-5(4H)-亚基)甲基)-2-甲氧基苯氧基)乙酸乙酯 |
| Canonical SMILES | O=C(OCC)COC1=CC=C(/C=C(SC(N)=N2)\C2=O)C=C1OC |
| 分子式 | C15H16N2O5S |
| 分子量 | 336.36 |
| 溶解度 | DMSO: 25 mg/mL (74.33 mM; ultrasonic and warming and heat to 80°C) |
| 储存条件 | 4°C, protect from light |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
| 产品描述 | CCI-007 is a small molecule with cytotoxic activity against infant leukemia with MLL rearrangements, with IC50 values of 2.5-6.2 μM in sensitive cells[1]. CCI-007 is a selective inhibitor of MLL-r, CALM-AF10 and SET-NUP214 leukemia[1].Following CCI-007 treatment for 24h, significant mitochondrial depolarization was observed in PER-485 cells as evidenced by a shift in JC-1 signal[1].Resistance to CCI-007 can occur by upregulation of MLL target gene expression[1].CCI-007 reverts the aberrant elevated transcription of disease-driving factors HOXA9, MEIS1, and CMYC downstream of the pathogenic MLL fusion protein, thereby inducing MLL-r leukemia cell death[2]. Cell Viability Assay[1] Cell Line: PER-485, MOLM-13, MV4;11 cells. [1]. Klaartje Somers, et al. CCI-007, a novel small molecule with cytotoxic activity against infant leukemia with MLL rearrangements. Oncotarget. 2016 Jul 19;7(29):46067-46087. [2]. Klaartje Somers, et al. A novel small molecule that kills a subset of MLL-rearranged leukemia cells by inducing mitochondrial dysfunction. Oncogene. 2019 May;38(20):3824-3842. |
| 维奥蛋白资源库 - 中文蛋白资源 CopyRight © 2010-2026 |